Genetically Engineered Probiotic Nanoplatform for Ultrasound-Enhanced Colorectal Cancer Therapy via Targeted...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Research

Background:

• Colorectal cancer (CRC) is a major global health concern with limited early detection and treatment options.
• Current therapeutic strategies often face challenges in tumor specificity and efficacy.

Purpose of the Study:

• To develop a multifunctional nanoplatform for integrated diagnosis and therapy of colorectal cancer.
• To enhance CRC treatment through real-time imaging, targeted drug delivery, and immune modulation.

Main Methods:

• Engineered *Escherichia coli* Nissle 1917 (EcN) producing ultrasound-responsive gas vesicles (GVs) for imaging.
• Folic acid-conjugated curcumin-loaded liposomes (Cur-Lip-FA) for targeted delivery and US-triggered release.
• Evaluation of the nanoplatform's efficacy in vitro and in vivo for CRC suppression and immune response activation.

Main Results:

• The EcNA@Cur-Lip-FA platform enabled noninvasive, real-time tumor imaging via ultrasound.
• Targeted delivery and US-triggered release of curcumin induced cancer cell death and activated anti-tumor immunity.
• Significant suppression of primary CRC and liver metastases was observed with good biocompatibility.

Conclusions:

• The developed nanoplatform integrates diagnosis and therapy for enhanced colorectal cancer treatment.
• This multifunctional approach shows promise for next-generation cancer theranostics.
• Further research can explore its potential in clinical settings for improved patient outcomes.